Literature DB >> 30397748

Reconstituted Discoidal High-Density Lipoproteins: Bioinspired Nanodiscs with Many Unexpected Applications.

Maki Tsujita1, Anna Wolska2, Daniel A P Gutmann3, Alan T Remaley2.   

Abstract

PURPOSE OF REVIEW: Summarize the initial discovery of discoidal high-density lipoprotein (HDL) in human plasma and review more recent innovations that span the use of reconstituted nanodisc HDL for membrane protein characterization to its use as a drug carrier and a novel therapeutic agent for cardiovascular disease. RECENT
FINDINGS: Using a wide variety of biophysical techniques, the structure and composition of endogenous discoidal HDL have now largely been solved. This has led to the development of new methods for the in vitro reconstitution of nanodisc HDL, which have proven to have a wide variety of biomedical applications. Nanodisc HDL has been used as a platform for mimicking the plasma membrane for the reconstitution and investigation of the structures of several plasma membrane proteins, such as cytochrome P450s and ABC transporters. Nanodisc HDL has also been designed as drug carriers to transport amphipathic, as well as hydrophobic small molecules, and has potential therapeutic applications for several diseases. Finally, nanodisc HDL itself like native discoidal HDL can mediate cholesterol efflux from cells and are currently being tested in late-stage clinical trials for cardiovascular disease. The discovery of the characterization of native discoidal HDL has inspired a new field of synthetic nanodisc HDL, which has offered a growing number of unanticipated biomedical applications.

Entities:  

Keywords:  Apolipoprotein A-I; CYP; Drug delivery; High-density lipoprotein (HDL); Mimetic peptides; Nanodiscs

Mesh:

Substances:

Year:  2018        PMID: 30397748     DOI: 10.1007/s11883-018-0759-1

Source DB:  PubMed          Journal:  Curr Atheroscler Rep        ISSN: 1523-3804            Impact factor:   5.113


  111 in total

Review 1.  High-Density Lipoproteins: Nature's Multifunctional Nanoparticles.

Authors:  Rui Kuai; Dan Li; Y Eugene Chen; James J Moon; Anna Schwendeman
Journal:  ACS Nano       Date:  2016-02-25       Impact factor: 15.881

2.  Interaction of apoprotein from porcine high-density lipoprotein with dimyristoly lecithin. 2. Nature of lipid-protein interaction.

Authors:  A L Andrews; D Atkinson; M D Barratt; E G Finer; H Hauser; R Henry; R B Leslie; N L Owens; M C Phillips; R N Robertson
Journal:  Eur J Biochem       Date:  1976-05-01

3.  PET Imaging of Tumor-Associated Macrophages with 89Zr-Labeled High-Density Lipoprotein Nanoparticles.

Authors:  Carlos Pérez-Medina; Jun Tang; Dalya Abdel-Atti; Brandon Hogstad; Miriam Merad; Edward A Fisher; Zahi A Fayad; Jason S Lewis; Willem J M Mulder; Thomas Reiner
Journal:  J Nucl Med       Date:  2015-06-25       Impact factor: 10.057

4.  Structure of the Human Lipid Exporter ABCA1.

Authors:  Hongwu Qian; Xin Zhao; Pingping Cao; Jianlin Lei; Nieng Yan; Xin Gong
Journal:  Cell       Date:  2017-06-08       Impact factor: 41.582

5.  Regression of coronary atherosclerosis with infusions of the high-density lipoprotein mimetic CER-001 in patients with more extensive plaque burden.

Authors:  Yu Kataoka; Jordan Andrews; MyNgan Duong; Tracy Nguyen; Nisha Schwarz; Jessica Fendler; Rishi Puri; Julie Butters; Constance Keyserling; John F Paolini; Jean-Louis Dasseux; Stephen J Nicholls
Journal:  Cardiovasc Diagn Ther       Date:  2017-06

Review 6.  Lipid-protein interactions in biological membranes: a structural perspective.

Authors:  A G Lee
Journal:  Biochim Biophys Acta       Date:  2003-05-02

7.  Rationale and design of Apo-I Event Reduction in Ischemic Syndromes I (AEGIS-I): A phase 2b, randomized, placebo-controlled, dose-ranging trial to investigate the safety and tolerability of CSL112, a reconstituted, infusible, human apoA-I, after acute myocardial infarction.

Authors:  C Michael Gibson; Serge Korjian; Pierluigi Tricoci; Yazan Daaboul; John H Alexander; Philippe G Steg; A Michael Lincoff; John J P Kastelein; Roxana Mehran; Denise D'Andrea; Bela Merkely; Maciej Zarebinski; Ton Oude Ophius; Robert A Harrington
Journal:  Am Heart J       Date:  2016-07-05       Impact factor: 4.749

8.  Interaction of free apolipoproteins with macrophages. Formation of high density lipoprotein-like lipoproteins and reduction of cellular cholesterol.

Authors:  H Hara; S Yokoyama
Journal:  J Biol Chem       Date:  1991-02-15       Impact factor: 5.157

9.  HDL and CER-001 Inverse-Dose Dependent Inhibition of Atherosclerotic Plaque Formation in apoE-/- Mice: Evidence of ABCA1 Down-Regulation.

Authors:  Claudine Tardy; Marine Goffinet; Nadia Boubekeur; Guy Cholez; Rose Ackermann; Gavin Sy; Constance Keyserling; Narendra Lalwani; John F Paolini; Jean-Louis Dasseux; Ronald Barbaras; Rudi Baron
Journal:  PLoS One       Date:  2015-09-03       Impact factor: 3.240

10.  Application of nanodisc technology for direct electrochemical investigation of plant cytochrome P450s and their NADPH P450 oxidoreductase.

Authors:  Krutika Bavishi; Tomas Laursen; Karen L Martinez; Birger Lindberg Møller; Eduardo Antonio Della Pia
Journal:  Sci Rep       Date:  2016-07-08       Impact factor: 4.379

View more
  6 in total

1.  Assembly and Characterization of Biocompatible Coenzyme Q10 -Enriched Lipid Nanoparticles.

Authors:  Anthony Moschetti; Lucas N Vine; Kyle Lethcoe; Ruben K Dagda; Patricia Ellison; Robert O Ryan
Journal:  Lipids       Date:  2020-02-19       Impact factor: 1.880

2.  Foam fractionation of a recombinant biosurfactant apolipoprotein.

Authors:  Kyle Lethcoe; Colin A Fox; Robert O Ryan
Journal:  J Biotechnol       Date:  2021-11-19       Impact factor: 3.307

Review 3.  Reconstituted HDL as a therapeutic delivery device.

Authors:  Colin A Fox; Anthony Moschetti; Robert O Ryan
Journal:  Biochim Biophys Acta Mol Cell Biol Lipids       Date:  2021-08-08       Impact factor: 5.228

Review 4.  Reconfiguring Nature's Cholesterol Accepting Lipoproteins as Nanoparticle Platforms for Transport and Delivery of Therapeutic and Imaging Agents.

Authors:  Skylar T Chuang; Siobanth Cruz; Vasanthy Narayanaswami
Journal:  Nanomaterials (Basel)       Date:  2020-05-08       Impact factor: 5.076

Review 5.  Apolipoprotein Mimetic Peptides: Potential New Therapies for Cardiovascular Diseases.

Authors:  Anna Wolska; Mart Reimund; Denis O Sviridov; Marcelo J Amar; Alan T Remaley
Journal:  Cells       Date:  2021-03-08       Impact factor: 6.600

6.  Apolipoprotein A-I in mouse cerebrospinal fluid derives from the liver and intestine via plasma high-density lipoproteins assembled by ABCA1 and LCAT.

Authors:  Maki Tsujita; Boris Vaisman; Liu Chengyu; Kasey C Vickers; Kei-Ichiro Okuhira; Sten Braesch-Andersen; Alan T Remaley
Journal:  FEBS Lett       Date:  2020-10-20       Impact factor: 4.124

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.